Systemic delivery of genes to striated muscles using adeno-associated viral vectors

Nature Medicine

Volumn 10, Issue 8, 2004, Pages 828-834

  Gregorevic, Paul ^a   Blankinship, Michael J ^a   Allen, James M ^a   Crawford, Robert W ^a   Meuse, Leonard ^a   Miller, Daniel G ^a   Russell, David W ^a   Chamberlain, Jeffrey S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; DYSTROPHIN; PARVOVIRUS VECTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; HEART MUSCLE; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SKELETAL MUSCLE; TISSUE SPECIFICITY; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

ANIMALS; CAPILLARY PERMEABILITY; CHROMATOGRAPHY, AFFINITY; DISEASE MODELS, ANIMAL; DNA PRIMERS; DYSTROPHIN; ENDOTHELIUM; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PARVOVIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ADENO-ASSOCIATED VIRUS; ANIMALIA; DNA VIRUSES; MAMMALIA; PARVOVIRUS;

EID: 4043092073     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1085     Document Type: Article

References (33)

1. Hoshijima, M. et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864-871 (2002).
2. Musaro, A. et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27, 195-200 (2001).
3. Harper, S.Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261 (2002).
4. Greelish, J.P. et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat. Med. 5, 439-443 (1999).
5. Bridges, C.R. et al. Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation. Ann. Thorac. Surg. 73, 1939-1946 (2002).
6. Huard, J. et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2, 107-115 (1995).
7. Cho, W.K. et al. Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. Hum. Gene Ther. 11, 701-714 (2000).
8. Zhang, G., Budker, V., Williams, P., Hanson, K. & Wolff, J.A. Surgical procedures for intravascular delivery of plasmid DNA to organs. Methods Enzymol. 346, 125-133 (2002).
9. Dellorusso, C. et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl. Acad. Sci. USA 99, 12979-12984 (2002).
10. Watchko, J. et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. 13, 1451-1460 (2002).
11. Halbert, C.L., Rutledge, E.A., Allen, J.M., Russell, D.W. & Miller, A.D. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74, 1524-1532 (2000).
12. Scott, J.M. et al. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul. Disord. 12, S23-S29 (2002).
13. Roberts, W.G. & Palade, G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108, 2369-2379 (1995).
14. Senger, D.R., Perruzzi, C.A., Feder, J. & Dvorak, H.F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46, 5629-5632 (1986).
15. Hauser, M.A. et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol. Ther. 2, 16-25 (2000).
16. Hartigan-O'Cormor, D., Kirk, C.J., Crawford, R., Mule, JJ. & Chamberlain, J.S. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol. Ther. 4, 525-533 (2001).
17. Grimm, D. et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102, 2412-2419 (2003).
18. Yuasa, K. et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. 9, 1576-1588 (2002).
19. Pinson, K.I., Dunbar, L., Samuelson, L. & Gumucio, D.L. Targeted disruption of the mouse villin gene does not impair the morphogenesis of microvilli. Dev. Dyn. 211, 109-121 (1998).
20. Petrof, B.J., Shrager, J.B., Stedman, H.H., Kelly, A.M. & Sweeney, H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA 90, 3710-3714 (1993).
21. Gregorevic, P. & Chamberlain, J.S. Gene therapy for muscular dystrophy - a review of promising progress. Expert Opin. Biol. Ther. 3, 803-814 (2003).
22. Sakamoto, M. et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem. Biophys. Res. Commun. 293, 1265-1272 (2002).
23. Ahmad, A., Brinson, M., Hodges, B.L., Chamberlain, J.S. & Amalfitano, A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum. Mol. Genet. 9, 2507-2515 (2000).
24. Phelps, S.F. et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet. 4, 1251-1258 (1995).
25. Arruda, V.R. et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol. Ther. 4, 586-592 (2001).
26. Herzog, R.W. et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum. Gene Ther. 13, 1281-1291 (2002).
27. Manno, C.S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972 (2003).
28. Eppler, S.M. et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther. 72, 20-32 (2002).
29. Herzog, R.W. et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5, 56-63 (1999).
30. Rutledge, E.A., Halbert, C.L. & Russell, D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309-319 (1998).
31. Grimm, D., Kern, A., Rittner, K. & Kleinschmidt, J.A. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther. 9, 2745-2760 (1998).
32. Halbert, C.L., Allen, J.M. & Miller, A.D. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J. Virol. 75, 6615-6624 (2001).
33. Rafael, J.A. et al. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J. Cell Biol. 134, 93-102 (1996).